{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"TG Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"TGTX"},"Address":{"label":"Address","value":"2 GANSEVOORT STREET,9TH FLOOR SUITE 475, NEW YORK, New York, 10014, United States"},"Phone":{"label":"Phone","value":"+1 212 554-4484"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor."},"CompanyUrl":{"label":"Company Url","value":"https://www.tgtherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Michael Sean Weiss","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}